INTRODUCTION {#sec1-1}
============

Ranolazine hydrochloride is an anti-ischemic agent. It was approved in January 2006 by the U.S. Food and Drug Administration (FDA) for the treatment of chronic stable angina. Based on current evidence, ranolazine has been included as a second-line antianginal in North-American and European guidelines for the management of chronic stable angina.\[[@ref1][@ref2]\] Since its approval, the drug has shown benefits beyond angina relief. Extended benefits have been observed in the management of arrhythmias, especially atrial fibrillation (AF), and in diastolic dysfunction, pulmonary hypertension (PH), and chemotherapy-related cardiotoxicity.\[[@ref3]\] Ranolazine has also shown promise in the management of diabetes mellitus.\[[@ref3]\]

In this article, we present a comprehensive review of ranolazine\'s pharmacology, mechanism of action, and recent preclinical and clinical evidence.

PHARMACOLOGY AND MECHANISM OF ACTION {#sec1-2}
====================================

Ranolazine is a piperazine derivative available as extended-release tablets of 500 or 1000 mg. Typical doses are 500--1000 mg twice daily. Plasma concentration peaks 2--5 h after oral administration with an elimination half-life of 2 h. The drug is metabolized principally in the liver and excreted principally through the kidneys \[[Table 1](#T1){ref-type="table"}\].\[[@ref4][@ref5]\]

###### 

Salient facts about ranolazine

  --------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pharmacology          Ranolazine is a piperazine derivative. In 2006 ranolazine received FDA approval for the treatment of chronic angina. Ranolazine is metabolized mainly by the CYP3A system
  Mechanism of action   It inhibits the late Na current in cardiac muscle thus preventing calcium overloading of heart muscle, which in turn reduces the tension and oxygen consumption in heart muscle
  Common use            Chronic stable angina
  Side effects          Dizziness, constipation, headache, nausea, syncope
  Promising role        Stable ischemic heart disease with diabetes mellitus, postcardio version and post-CABG atrial fibrillation
  --------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

FDA: Food and Drug Administration, CABG: Coronary artery bypass grafting

Ranolazine acts by blocking late sodium channels (I~Na~).\[[@ref6]\] It thus prevents downstream rise in cytosolic Ca+2 concentrations, which translates into mechanical effects including a decrease in left ventricular wall tension and increase in coronary blood flow, leading to angina relief. I~Na~ blocking also leads to stabilization of the myocardial cell membrane, likely responsible for its anti-arrhythmic effect. The late rectifier K + current inhibition contributes to its anti-arrhythmic effect. With regard to its beneficial effect in diabetes, it has been postulated that ranolazine blocks Na + channels in the pancreatic islet alpha-cells to inhibit glucagon release. Studies have also revealed its role in pancreatic beta-cell preservation\[[@ref7][@ref8]\] \[[Figure 1](#F1){ref-type="fig"}\].

![Ranolazine: Mechanism of action](HV-19-88-g001){#F1}

ROLE AS AN ANTIANGINAL {#sec1-3}
======================

Ranolazine is a piperazine derivative approved by the FDA in 2006 for treatment of chronic stable angina.\[[@ref9]\] The Monotherapy Assessment of Ranolazine in Stable Angina trial showed that ranolazine monotherapy improved exercise duration in angina.\[[@ref10]\] The Combination Assessment of Ranolazine in Stable Angina (CARISA) trial demonstrated improved exercise duration with ranolazineas a component of combination therapy.\[[@ref11]\] In the Efficacy of Ranolazine in Chronic Angina trial, treatment with ranolazine improved self-reported angina.\[[@ref12]\] These data have helped establish the role of ranolazine in refractory stable angina \[[Table 2](#T2){ref-type="table"}\].

###### 

Clinical trials with ranolazine ([www.clinicaltrials.gov](www.clinicaltrials.gov))

  Title of the trial                                                                                                                                                                                                                    Phase of the trial   Clinicaltrails.gov number   Purpose                                                                                                                                                                                                                                               Results
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------- --------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Targeting right ventricle in pulmonary hypertension                                                                                                                                                                                   Interventional       NCT02829034                 This study is assessing whether addition of ranolazine in patients with PAH with RV dysfunction (EF \<45%) helps with outcomes                                                                                                                        Recruiting participants. Will be completed by December 2018
  Treatment With Ranolazine in MCD: Impact on Angina Myocardial Ischemia (RWISE)                                                                                                                                                        Interventional       NCT01342029                 To assess role of ranolazine in patients with microvascular angina                                                                                                                                                                                    Short-term treatment with ranolazine was not effective in decreasing angina
  A Phase I Study of ranolazine acute administration and short-term administration in pulmonary arterial hypertension                                                                                                                   Phase 1              NCT01757808                 To assess the safety of ranolazine in PAH patients receiving 1 or more background therapies                                                                                                                                                           Ranolazine in PAH patients was safe
  Effect of ranolazine on glucagon secretion in subjects with type 2 diabetes mellitus                                                                                                                                                  Phase 1              NCT01843127                 To explore the anti-hyperglycemic effect of ranolazine                                                                                                                                                                                                
  Long-term prophylactic therapy of congenital long QT syndrome type III with ranolazine                                                                                                                                                Phase 2              NCT01728025                 To assess whether ranolazine reduces arrhythmia risk in patients with long QT syndrome type III                                                                                                                                                       
  Microvascular coronary disease In women: Impact of ranolazine                                                                                                                                                                         Phase 2              NCT00570089                 To evaluate the impact of ranolazine in patients with subendocardial ischemia due to microvascular endothelial dysfunction                                                                                                                            In women with angina with evidence of ischemia due to microvascular endothelial dysfunction, treatment with ranolazine improves angina
  Ranolazine in Atrial Fibrillation following An Electrical Cardioversion (RAFFAELLO)                                                                                                                                                   Phase 2              NCT01534962                 Comparison of efficacy of three dose schedules (375 mg, 500 mg, 750 mg twice daily) of ranolazine in maintaining sinus rhythm after successful cardioversion                                                                                          No dose of ranolazine significantly prolonged the time to atrial fibrillation recurrence. But combined 500 mg and 750 mg groups showed reduced recurrence risk
  A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination on Atrial Fibrillation Burden in Subjects With Paroxysmal Atrial Fibrillation (HARMONY)                                              Phase 2              NCT01522651                 To assess whether treatment with ranolazine and low dose dronedarone reduces the burden of atrial fibrillation in patients with paroxysmal atrial fibrillation. Also to assess whether the combination is better than the individual components       The combination showed synergistic reduction in atrial fibrillation burden with good tolerance and safety
  Exploratory study to access the metabolic effects of ranolazine when added to ongoing noninsulin antidiabetic therapy in subjects with type 2 diabetes mellitus                                                                       Phase 2              NCT01163721                 To evaluate the metabolic effects of ranolazine in diabetic patients on noninsulin therapy                                                                                                                                                            
  Ranolazine mediated PVC reduction in ischemic heart disease                                                                                                                                                                           Phase 2              NCT02360397                 Percent change in PVC burden after treatment with ranolazine                                                                                                                                                                                          
  A Study of Ranolazine in Patients With Heart Failure With Preserved Ejection Fraction (RALI-DHF)                                                                                                                                      Phase 2              NCT01163734                 To look for the changes in hemodynamic and echocardiographic parameters after treatment with ranolazine in coronary artery disease patients with symptomatic heart failure and preserved EF                                                           Ranolazine improved measures of hemodynamics but that there was no improvement in relaxation parameters
  Improvement of Subjective Well-Being by Ranolazine Among Unrevascularized Chronic Stable Coronary Artery Disease Patients (IMWELL)                                                                                                    Phase 2              NCT02265796                 To assess the role of ranolazine in chronic stable angina patients who did not undergo revascularization                                                                                                                                              In chronic stable angina patients with documented myocardial ischemia, ranolazine did not improve angina symptoms at 16 weeks
  Effects of ranolazine in patients with angina due to right ventricular ischemia in pulmonary arterial hypertension                                                                                                                    Phase 3              NCT01174173                 To assess the effect of ranolazine on functional class, exercise capacity and quality of life                                                                                                                                                         Ranolazine was well tolerated. It improved symptoms and echocardiographic parameters but did not have effects on invasive hemodynamic parameters
  Randomized double-blind control trial on effects of ranolazine on new-onset atrial fibrillation rates in postoperative cardiac surgery patients                                                                                       Phase 3              NCT01590979                 To evaluate the prophylactic effects of ranolazine on new-onset atrial fibrillation in post-CABG and valve surgery patients                                                                                                                           Very small sample size
  Reduction of ischemic myocardium with ranolazine treatment in patients with acute myocardial ischemia                                                                                                                                 Phase 3              NCT01797484                 To examine the effect of ranolazine on ischemic myocardium in acute myocardial ischemia                                                                                                                                                               
  Ranolazine monotherapy in subjects with type 2 diabetes mellitus                                                                                                                                                                      Phase 3              NCT01472185                 To determine the effect of ranolazine when given as monotherapy, on glycemic control in subjects with type 2 diabetes mellitus and inadequate glycemic control on diet and exercise                                                                   Treatment with ranolazine for 24 weeks showed a reduction in HBA1c and other glycemic measures
  Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Patients With Diabetes and Suspected or Known Coronary Artery Disease (RAND CFR)                                                                                        Phase 3              NCT01754259                 To assess the role of ranolazine on coronary vasodilator reserve or CFR                                                                                                                                                                               
  Ranolazine when added to glimepiride in subjects with type 2 diabetes mellitus                                                                                                                                                        Phase 3              NCT01494987                 To evaluate the change in HBA1c level after 24 weeks of treatment with ranolazine in diabetic patients over and above that of glimepiride                                                                                                             
  Metabolic Efficiency with Ranolazine for Less Ischemia in non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial                                                                                                            Phase 3              NCT00099788                 To determine the efficacy and safety of ranolazine during long-term treatment of NSTEMI                                                                                                                                                               Addition of ranolazine to standard treatments of NSTEMI was not effective in reducing cardiovascular events
  The effect of ranolazine on cardiac arrhythmias and microvolt T-wave alternans in patients with significant left ventricular dysfunction                                                                                              Phase 3              NCT00998218                 To evaluate the role of ranolazine on arrhythmia and microvolt T-wave alternans in patients who already underwent ICD implantation for primary prophylaxis and those who had a clinically significant arrhythmia episode prompting ICD implantation   
  Ranolazine in patients with incomplete revascularization after PCI (RIVER-PCI)                                                                                                                                                        Phase 3              NCT01442038                 To evaluate the role of ranolazine as part of the standard therapy in chronic stable angina patients incompletely revascularized                                                                                                                      Ranolazine failed to reduce the rates of ischemia-driven revascularisation or hospitalization
  Ranolazine SR at a Dose of 1000 mg Twice a Day in Patients With Chronic Angina Who Remain Symptomatic Despite Treatment With Amlodipine (ERICA)                                                                                       Phase 3              NCT00091429                 To assess the role of ranolazine in chronic stable angina patients who remain symptomatic even after maximum tolerated dose of amlodipine                                                                                                             Ranolazine significantly reduced the frequency of angina and nitroglycerin consumption
  A phase 3 study of Ranolazine in subjects with type 2 diabetes who are inadequately controlled on metformin alone                                                                                                                     Phase 3              NCT01555164                 To assess the anti-hyperglycemic role of ranolazine when added to metformin in type 2 diabetes mellitus                                                                                                                                               
  Microvascular Assessment of Ranolazine in nonobstructive Atherosclerosis (MARINA)                                                                                                                                                     Phase 4              NCT02147067                 To assess the effects of ranolazineon symptoms of chest pain or chest tightness measured by Seattle Angina Questionnaire score in patients with microvascular disease                                                                                 Recruiting patients
  Pharmacokinetics of single-dose oral ranolazine in hemodialysis patients                                                                                                                                                              Phase 4              NCT01435174                 To study the pharmacokinetic parameters of single dose ranolazine in end stage renal disease patients                                                                                                                                                 Not yet published
  Ranolazine for the Treatment of Angina in Hypertrophic Cardiomyopathy Investigation (RHYME)                                                                                                                                           Phase 4              NCT01721967                 To evaluate the safety and efficacy of ranolazine in HCM patients. Also to assess the effect on anginal symptoms in HCM patients                                                                                                                      
  Effects of Ranolazine and Exercise on Daily Physical Activity Trial (EREDA)                                                                                                                                                           Phase 4              NCT01948310                 To assess whether treatment with ranolazine and subsequent intense training exercise improves exercise tolerance and oxygen consumption                                                                                                               
  Impact of Ranolazine on Inflammatory, Thrombogenic, Lipogenic, Biomarkers in Women With Angina and Metabolic Syndrome (IRMA)                                                                                                          Phase 4              NCT02252406                 To evaluate the impact of ranolazine in decreasing angina frequency in women with angina and metabolic syndrome                                                                                                                                       Currently recruiting patients
  Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention (REPTAR)                                                                                                                         Phase 4              NCT03044964                 To evaluate the activity level and exercise tolerance after ranolazine treatment in patients with deferred percutaneous intervention due to FFR ≥0.81                                                                                                 Currently recruiting patients
  Study of ranolazine in the treatment of pulmonary hypertension associated with diastolic left ventricular dysfunction                                                                                                                 Phase 4              NCT02133352                 To evaluate the safety and efficacy of ranolazine in patients with pulmonary hypertension associated with left ventricular diastolic dysfunction                                                                                                      
  Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) trial                                                                                                                                        Phase 4              NCT01425359                 To evaluate the role of ranolazine in decreasing weekly angina frequency in chronic stable angina patients with diabetes mellitus                                                                                                                     Ranolazine reduced angina frequency and nitroglycerin use and was well tolerated
  An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Women's Ischemia Symptom Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)   Phase 4              NCT00644332                 To evaluate the validity, reliability, and responsiveness of the newly developed WISQ based on changes in angina symptomatology in a female angina population treated with ranolazine                                                                 

MCD: Microvascular coronary dysfunction, PCI: Percutaneous coronary intervention, PVC: Premature ventricular contraction, FFR: Fractional flow reserve, PAH: Pulmonary arterial hypertension, RV: Right ventricular, EF: Ejection fraction, CFR: Coronary flow reserve, HBA1c: Hemoglobin A1c, ICD: Implantable cardioverter-defibrillator, HCM: Hypertrophic cardiomyopathy, WISQ: Women's Ischemia Symptom Questionnaire, CABG: Coronary artery bypass grafting, NSTEMI: Non-ST elevation myocardial infarction

ROLE BEYOND ANGINA {#sec1-4}
==================

Ranolazine in arrhythmias {#sec2-1}
-------------------------

Ranolazine has a multi-channel effect on cardiomyocytes. It inhibits late I~Na~, I~Kr~, I~Ca~, and I~Na-Ca~ current. There is no effect on I~to~, I~K1~, and I~Ks~. It reduces Na^+^ and Ca^++^ overload in cardiac myocytes which leads to its antiarrhythmic effect.\[[@ref13]\] Ranolazine also decreases early and delayed afterdepolarizations.\[[@ref14]\] Ranolazine displays selective action on atrial cardiomyocytes. A possible mechanism for this selectivity has been borne out in a study in rabbit hearts. Atrial cells showed more I~Na~ conductance, more negative activation and inactivation potentials of I~Na~ and more trapping of ranolazine in the inactivated Na channel.\[[@ref15]\]

There is also a possible role of ranolazine in molecular signaling pathways that prevent AF. In a rat model of Ach-CaCl~2~ induced AF, ranolazine improved mitochondrial function reduced oxidative stress and decreased atrial myoyte apoptosis. It also increased protective signaling via the Akt/mTOR pathway.\[[@ref16]\]

In chronic kidney disease patients, there is an increased incidence of AF, potentially mediated by FGF-23 on late Na and calcium channels. This increases arrhythmogenesis in pulmonary vein cardiomyocytes. By inhibiting the late Na current and preventing Ca overload, ranolazine may have a role in preventing AF in this patient subset.\[[@ref17]\]

### Preclinical data {#sec3-1}

A preclinical trial compared the effect of dofetilide and ranolazine on acutely induced AF in 8 horses. Ranolazine in combination with dofetilide was found to convert AF to sinus rhythm, and decrease AF vulnerability and duration compared with either drug alone. Neither drug had any effect on the atrial effective refractory period.\[[@ref18]\] In another preclinical study ranolazine was compared with vernakalant for cardioversion of acutely induced AF in 15 rabbit hearts. AF was induced with atrial burst pacing and acetylcholine/isoproterenol. Ranolazine and vernakalant had similar efficacy in preventing AF.

As opposed to vernakalant, ranolazine significantly increased the atrial effective refractory period.\[[@ref19]\] Ranolazine has been tested in combination with ivabradine in AF in pigs. A combination of the two drugs decreased ventricular rate by reducing conduction at the AV node (increased A-H interval) and decreasing the dominant AF frequency. This was achieved at clinically safe levels without decreasing cardiac contractility or prolongation of the QT interval.\[[@ref20]\] AF is common in heart failure and many anti-arrhythmic agents are contraindicated.

Ranolazine was studied in a canine-model right atrial and left ventricular preparation with tachycardia-induced heart failure. It suppressed induction of AF by increasing the atrial effective refractory period and atrial conduction time. No proarrhythmic effect on the ventricle was noted.\[[@ref21]\] In a porcine model of catecholaminergic polymorphic ventricular tachycardia (VT), ranolazine reduced VT and T wave alternans incidence.\[[@ref22]\] Ranolazine has also been shown noninferior to lidocaine and sotalol in preventing ischemia-reperfusion induced VT in a rat model.\[[@ref23]\] Two preclinical trials of ranolazine in a rat model of long QT syndrome have shown promising results. Ranolazine reduced prolongation of the QT interval, suppressed early after depolarizations and the frequency of torsades de pointes.\[[@ref24][@ref25]\]

### Clinical data {#sec3-2}

Metabolic efficiency with ranolazine for less ischemia in nonST-elevation acute coronary syndrome thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) was a large randomized controlled trial involving 6560 patients to evaluate the efficacy and safety of ranolazine in the nonST-elevation myocardial infarction setting. It showed that treatment with ranolazine resulted in a significantly lower incidence of VT, supraventricular tachycardia, and ventricular pauses compared to placebo. However, its addition to standard treatment for acute coronary syndromes was not effective in reducing major cardiovascular events.\[[@ref26][@ref27]\]

Ranolazine was evaluated in patients with coronary artery disease and paroxysmal AF who had a dual chamber pacemaker capable of detecting AF. Ranolazine 375 mg twice daily compared to placebo reduced the total time in AF and mean AF duration. There was no significant difference in QTc.\[[@ref28]\] In the RAFAELLO trial, 241 patients with AF who underwent electrical cardioversion were randomized 2 h after the procedure to receive either Ranolazine 375 mg twice daily, 500 mg twice daily, 750 mg twice daily or placebo. Ranolazine was safe and well tolerated. It did not prolong time to AF recurrence. The 500 mg and 750 mg arms combined showed a reduction in AF recurrence with borderline statistical significance.\[[@ref29]\]

Koskinas *et al*. showed that ranolazine has an additive effect with amiodarone in conversion of AF to sinus rhythm.\[[@ref30]\] Tsanaxidis *et al*. showed a single 1000 mg oral dose of ranolazine added to amiodarone leads to quicker return to sinus rhythm and a higher conversion rate to sinus than amiodarone alone. The addition of ranolazine had no adverse impact on left ventricular function.\[[@ref31]\]

Two meta-analyses have confirmed the additive benefit of ranolazine to amiodarone in AF. The addition of ranolazine quickens the time to cardioversion of AF. It also helps prevent new-onset AF in people with sinus rhythm.\[[@ref32][@ref33]\] The HARMONY trial revealed that a combination of ranolazine and dronedarone was effective in significantly reducing AF burden compared to placebo.\[[@ref34]\] To evaluate the possible mechanism for this synergistic effect, patch clamp experiments from atrial myocytes of patients in sinus rhythm were conducted. They revealed increased action potential duration, decreased sarcoplasmic reticulum calcium leak and membrane hyperpolarization when ranolazine and dronedarone were used alone or in combination. These inhibitory effects may partly explain the results of HARMONY trial.\[[@ref35]\] Several small studies have shown that ranolazine in moderate doses significantly shortens the mean time of conversion from AF to sinus rhythm and also reduces the occurrence of AF in coronary artery bypass grafting (CABG).\[[@ref36][@ref37][@ref38][@ref39][@ref40]\]

Another trial evaluated the role of ranolazine in postoperative AF (POAF). Patients undergoing CABG, valve surgery, or a combination were included. The addition of ranolazine to standard therapy significantly decreased POAF frequency. There was no effect on Insensitive Care Unit stay or cardiovascular mortality, but the 30 days cardiovascular readmission rate was reduced.\[[@ref40]\] The Ranolazine Implantable Cardioverter-Defibrillator trial was conducted to compare the efficacy of ranolazine with placebo in preventing VT in patients with ICDs. The endpoint measured was ventricular arrhythmia requiring ICD intervention. This study has been completed, and results are awaited.\[[@ref41]\] Intravenous ranolazine has also been found to decrease QT prolongation in 5 patients of LQT3 in a concentration-dependent manner.\[[@ref42]\]

Existing evidence suggests that ranolazine is effective in the management of AF, especially in postcardioversion and post-CABG situations, and potentially additive with amiodarone and dronedarone in pharmacological cardioversion. However, these small studies are not sufficiently powered to provide conclusive evidence.

Ranolazine in ischemic reperfusion injury {#sec2-2}
-----------------------------------------

Ischemia-reperfusion is associated with diastolic calcium overload and reduction in the amplitude of intracellular calcium transients. Application of ranolazine during ischemia-reperfusion significantly improved intracellular calcium handling. Ranolazine increases calcium concentrations in sarcoplasmic reticulum, thus preventing intracellular calcium overload in diastole, which in turn preserves intracellular calcium transients.\[[@ref43]\]

### Preclinical data {#sec3-3}

In animal studies, ranolazine shown several benefits. It reduces myocardial infarct size and improves left ventricular function. Animals in the ranolazine-treated arm were found to have a decrease in ischemia/reperfusion-induced arrhythmias and improved outcomes in heart failure.\[[@ref44]\]

### Clinical data {#sec3-4}

Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) was a large, randomized, multi-center, double-blind, phase three trial, designed to investigate the effect of ranolazine in reducing ischemia-driven revascularization and hospitalization in patients who had incomplete revascularization after PCI.\[[@ref45]\] This trial analyzed 2604 patients from 245 centers from 4 countries and followed them for a median of 643 days. Patients received either ranolazine 1000 mg twice daily or placebo. The primary endpoint was time to first ischemia related event, either hospitalization or revascularization, which occurred in 26% in the ranolazine and 28% in the placebo group, which was not a statistically significant difference.\[[@ref45]\]

Secondary analysis of the RIVER-PCI study showed the ranolazine arm had improved quality of life at 6- and 12 months postrevascularization. Improvement in angina was noted in the ranolazine arm at 6 months postrevascularization, but this benefit did not persist beyond a year. Improvements in angina was especially pronounced in diabetic patients and those with severe baseline symptoms.\[[@ref46]\]

Considering the outcomes from RIVER PCI trial, ranolazine may have a role in the treatment of angina after incomplete revascularization, especially in diabetic patients, but dedicated prospective studies are needed to confirm this hypothesis.

Ranolazine in pulmonary hypertension {#sec2-3}
------------------------------------

Studies have suggested that ranolazine may have anti-arrhythmic and anti-inflammatory effects on the left heart.\[[@ref47]\] Although the left and right ventricle have physiological differences, pathological processes such as ischemia, diastolic calcium overload, oxidative stress, and fibrosis are equally prevalent in both left and right heart chambers. This has prompted research to assess the potential role of ranolazine in PH.

### Preclinical data {#sec3-5}

Lee *et al*. revealed that treatment with ranolazine reduced right ventricular (RV) hypertrophy and fibrosis in monocrotaline-induced PH in rats. They also revealed reduced levels of the B-type natriuretic peptide (BNP) in ranolazine treated rats.\[[@ref48]\] Rocchetti *et al*. showed that treatment with ranolazine prevents constitutive enhancement of the late sodium current, thus blunting myocardial remodeling in a rat model.\[[@ref49]\]

### Clinical data {#sec3-6}

Evidence to define the role of ranolazine in PH patients remains preliminary. A phase I study showed that ranolazine is safe in patients with pulmonary arterial hypertension (PAH) without any acute hemodynamic changes. However, PAH patients treated with ranolazine receiving background pulmonary vasodilator therapies inconsistently reached therapeutic ranolazine levels.\[[@ref50]\] In another pilot study by Khan *et al*., ranolazine treatment was found to be safe and well tolerated in PAH patients. After 3 months of treatment with ranolazine, patients showed improvements in functional class, decrease in RV size, improvements in RV function measured by strain echocardiography, and improvement in exercise time. Despite these beneficial actions, ranolazine failed to show improvements in hemodynamic parameters.\[[@ref51]\]

Further studies are warranted to study the role of ranolazine in the management of PH.

Ranolazine in heart failure {#sec2-4}
---------------------------

### Preclinical data {#sec3-7}

Hypertensive rats with altered diastolic function treated with ranolazine showed improvements in diastolic parameters. Treatment with ranolazine improved the rate of LV pressure change (dp/dt), decreased LV end diastolic pressure (LVEDP), and improved the end-diastolic pressure-volume relationship. In addition, ranolazine treatment decreased LV hypertrophy.\[[@ref52]\]

### Clinical data {#sec3-8}

The effects of ranolazine on diastolic function parameters were heterogeneous. Pilot studies demonstrated that treatment with ranolazine improved echocardiographic diastolic parameters.\[[@ref53][@ref54]\] RALI-DHF was a small, single center, prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the role of ranolazine on diastolic parameters. Patients with LV ejection fraction \>45% with altered diastolic function parameters and elevated NT-Pro BNP (\>220 pg/ml) were included. Ranolazine was given as continuous intravenous infusion for 24 h followed by oral therapy for next 13 days. Ranolazine infusion improved LVEDP and pulmonary capillary wedge pressure. Mean pulmonary artery pressure showed a trend toward improvement, but NT-proBNP levels did not change.\[[@ref55][@ref56]\] Murray and Colombo showed that ranolazine added to guideline-directed pharmacotherapy for congestive heart failure, preserved and even improved left ventricular ejection fraction and autonomic measures when treatment was continued for 24 months.\[[@ref57]\] Venkataraman *et al*. showed in a small study that treatment with ranolazine improved systolic and diastolic LV dyssynchrony.\[[@ref58]\]

Ranolazine is also a partial fatty acid beta-oxidation inhibitor at higher serum concentration compared to the concentration required for inhibition of late sodium current.\[[@ref59]\] Ranolazine at higher doses may have cardioprotective actions in patients with heart failure.\[[@ref59]\] These experimental studies will likely help pave the way for larger clinical studies to further assess the role of ranolazine in heart failure.

Ranolazine in the prevention of chemotherapy-induced cardiotoxicity {#sec2-5}
-------------------------------------------------------------------

Anthracyclines probably cause hyperactivation of late inward sodium current which ultimately leads to cytosolic calcium overload. Simultaneously, anthracyclines also induce reactive oxygen species production. Both these mechanisms are responsible for sustained oxidative and energetic stresses, and lead to cardiomyocyte and cardiac stem cell death.\[[@ref60]\]

Preclinical study {#sec2-6}
-----------------

In a mouse model, treatment with ranolazine prevents doxorubicin induced left ventricular dilatation and dysfunction. Treatment with ranolazine also prevents increment in atrial natriuretic peptide, BNP, connective tissue growth factor, and matrix metalloproteinase 2 mRNA elevations seen with doxorubicin treatment.

This suggests that ranolazine may be effective in preventing direct cardiomyocyte injury and may decrease cardiomyocyte wall tension exerted by chemotherapeutic agents.\[[@ref61]\] There is paucity of data in this area but results of the INTERACT study are awaited. INTERACT is an open label, multi-center, phase IIB study designed to assess the potentially beneficial effects of ranolzine on post-chemotherapy diastolic dysfunction.\[[@ref62]\]

Role in diabetes mellitus {#sec2-7}
-------------------------

### Preclinical data {#sec3-9}

An animal study showed that ranolazine increases pancreatic beta cell survival and improves glucose homeostasis in streptozotocin-induced diabetes in mice.\[[@ref8]\] A recent study by Dhalla *et al*. revealed that the anti-hyperglyemic effect of ranolazine in humans results predominantly from a unique blockade of Pancreatic α-cell voltage-gated Na(+) channels (NaChs), which leads to decreases in basal and postprandial glucagon secretion.\[[@ref7]\]

### Clinical data {#sec3-10}

The CARISA trial revealed that ranolazine treatment was associated with a reduction in hemoglobin A1c (HBA1c) levels in patients with stable angina. In this trial, HbA1c was not a prespecified outcome and further stratification of results based on insulin or oral anti-hyperglycemic usage was not possible.\[[@ref11]\] A *post hoc* analysis of the MERLIN-TIMI 36 trial demonstrated a reduction in HbA1c of 0.64% in diabetic patients randomized to the ranolazine arm. Fasting plasma glucose was also significantly reduced by a mean of 25.7 mg/dl. The MERLIN-TIMI trial was not designed to study glycemic outcomes, which remains a limitation of this trial.\[[@ref63][@ref64]\]

Trials evaluating the anti-hyperglycemic effect of ranolazine monotherapy in diabetic patients have revealed that treatment with ranolazine can reduce HBA1c level by 0.51%--0.56% compared to placebo, allowing a greater number of patients to achieve their glycemic goal.\[[@ref65][@ref66]\] This may be related to some extent to a decrease in insulin resistance.\[[@ref67]\] The magnitude of reduction of angina and reduction in rescue nitrate usage were greater in diabetic patients in the TERISA trial.\[[@ref68]\] Recently, a secondary analysis of the RIVER-PCI trial evaluated 961 diabetic patients with angina and incomplete revascularization after PCI. It showed a further reduction in angina frequency in patients with HbA1c ≥7.5% compared to those with a HbA1c \<7.5%.\[[@ref69]\] Considering the data available on the anti-hyperglycemic effect of ranolazine, it may have a place in the management of stable ischemic heart disease with diabetes.

Ranolazine in peripheral arterial disease {#sec2-8}
-----------------------------------------

Ranolazine reduces cardiac ischemia by selective deactivation of the late sodium current. Skeletal muscles also contain sodium channels which have both rapid and slow phases. Ischemia induced changes in the sodium channels of skeletal muscles may respond to ranolazine in manner similar as does ischemic myocardium. Ranolazine also improves endothelial function. In a pig model, intra-femoral injection of ranolazine causes persistent dilatation of the arterial bed compared to nitroglycerin. This may be secondary to an α1-adrenergic receptor blocking effect without altering the heart rate or systemic blood pressure.\[[@ref70]\] In a pilot study involving 45 patients with intermittent claudication, ranolazine 1000 mg BID showed an increase in peak walking time in comparison to placebo. Although ranolazine did not improve the ankle brachial index at rest, patients with severe intermittent claudication had an approximately 40% increase in walking time than placebo, comparable to cilostazol. Although the sample size was small, it has led to further research.\[[@ref71]\] The Supervised Treadmill Exercise and Ranolazine for Intermittent Claudication of Lower Extremities, a randomized trial, is being conducted to compare the efficacy of ranolazine with supervised treadmill exercise versus placebo and supervised treadmill exercise. The results are not yet published.\[[@ref72]\]

Ranolazine in myotonia-congenita {#sec2-9}
--------------------------------

Myotonia Congenita (MC) is a chloride channel mutation disorder characterized by muscle hyperexcitability. It adversely impacts quality of life by excessive muscle stiffness. Muscle stiffness improves with exercise, which is also called warm-up. A slow inactivation of sodium channel is responsible for the warm-up phenomenon. Ranolazine promotes slow inactivation of sodium channel, which may offer therapeutic potential to these patients. In a mouse model, ranolazine improved muscle functioning compared to mexiletine without major side effects.\[[@ref73]\]

In a recent pilot study involving 13 MC patients, ranolazine showed improvement in terms of clinical and electromyography (EMG) assessment of MC. Mexiletine may not be suitable for some patients because of gastrointestinal side effects. In this population, ranolazine may serve as an alternative.\[[@ref69]\] Recently, a phase 2 trial is ongoing to evaluate the effect of ranolazine in MC, Paramyotonia Congenita, and Myotonic Dystrophy Type 1. Patients with the above mentioned conditions will be randomized to receive either ranolazine 500 mg twice daily for 2 weeks followed by 1000 mg twice daily for another 2 weeks versus placebo. Primary outcomes are quality of life measurements for health and neuromuscular disease, and EMG to assess for changes in muscle potentials and performance. It is a phase 2 trial to mainly assess the safety profile of the drug in these neuromuscular conditions.\[[@ref73]\]

Ranolazine in hypertrophic cardiomyopathy {#sec2-10}
-----------------------------------------

### Preclinical data {#sec3-11}

Ranolazine was studied in transgenic mice carrying troponin T mutations responsible for hypertrophic cardiomyopathy (HCM). At therapeutic plasma concentrations, ranolazine prevented the development of HCM phenotype in these genotype positive mice. It reduced interventricular septum thickness, left ventricular fibrosis, left atrial enlargement, diastolic dysfunction, left ventricular hypercontractility, and improved left ventricular volume.\[[@ref74]\] An electromechanical study of human cardiomyocytes harvested from septal myectomy specimens in HCM showed electrophysiological remodelling with enhanced Ca-calmodulin kinase II dependent signaling and phosphorylation leading to abnormal calcium handling.\[[@ref75]\] This causes calcium overload, arrhythmogenesis, and diastolic dysfunction, which can be reversed *in vitro* by ranolazine.\[[@ref76]\] The negative inotropic action of ranolazine may decrease dynamic LV outflow tract obstruction in HCM. Ranolazine has also been shown to decrease refractory angina in HCM.\[[@ref77]\]

CONCLUSION AND FUTURE DIRECTIONS {#sec1-5}
================================

By preventing calcium overloading and reducing diastolic tension in cardiomyocytes, ranolazine is an important adjunct in the management of stable angina pectoris. Ranolazine may be particularly attractive in diabetic patients with angina since it leads to a reduction in glucose levels. Experimental studies showed promising role in the treatment of postcardioversion and post-CABG AF, heart failure, PH, peripheral arterial disease, MC, HCM, and in prevention of chemotherapy-induced cardiotoxicity.
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